Urology Times Newsletter

CLINICAL UPDATES

Intervention reduces post-RP opioid prescriptions

A simple intervention aiming to curb the contribution of postoperative pain medication prescribing to the opioid crisis was shown to reduce post-discharge opioid prescribing and use and increase opioid disposal without seeming to jeopardize pain control for patients who had undergone radical prostatectomy.

Learn more

Video - PCa focal therapy: Who are the best candidates?

Scott Eggener, MD, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

Watch the video

5-year cancer control comparable for focal therapy, RP

A multicenter study in the United Kingdom found 5-year prostate cancer control rates following treatment with focal therapy are similar to those of patients who have undergone radical prostatectomy, even when accounting for variation in tumor location, size, and risk.

Get the data

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

Optimizing treatment decisions in mCRPC

In this Urology Times^® supplement, a roundtable of expert urologists and oncologists addresses common questions about patient evaluation and management of castration-resistant prostate cancer (CRPC) and high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including the role and impact of the commercially available androgen receptor splice variant 7 (AR-V7) test to guide treatment decisions for men with metastatic CRPC.

Read it now.